Generics - Financial, Legal

Filter

Current filters:

FinancialLegal

Popular Filters

Lundbeck files appeal over EC pay-for-delay fine

02-09-2013

Denmark-based CNS specialist drugmaker Lundbeck (LUND: CO) has filed its appeal against the European…

citalopramEuropeFinancialGenericsLegalLundbeckPharmaceutical

Pharma associations strongly support Senate bill on FDA User Fees sequestration exemptions

05-08-2013

In the USA last week, Mark Pryor (Democrat, Arkansas), chairman of the Senate Appropriations Subcommittee…

BiotechnologyFinancialGenericsLegalNorth AmericaPharmaceuticalPolitics

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

US DoJ says Ranbaxy pleads guilty and agrees to pay $500 million in settlements

14-05-2013

In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA, a subsidiary…

Asia-PacificDaiichi SankyoFinancialGenericsLegalNorth AmericaProductionRanbaxy LaboratoriesRegulation

Dr Reddy's in $22.5 million settlement with Nordion

24-03-2013

India's second largest drugmaker Dr Reddy's Laboratories (NYSE: RDY) said last Friday (March 22) that…

Dr Reddy's LaboratoriesFinancialGenericsLegalNordion

Par Pharma agrees $45 million settlement over off-label Megace ES promotion

07-03-2013

US generic drugmaker Par Pharmaceutical NYSE: PRX) pleaded guilty in federal court yesterday (March 6)…

FinancialGenericsLegalMarkets & MarketingMegace ESMetabolicsNorth AmericaPar PharmaceuticalPharmaceutical

Merck & Co to pay $688 million to settle investor law suits; Teva could face $2.1 billion damages

15-02-2013

US pharma giant Merck & Co (NYSE: MRK) said yesterday that it has reached an agreement in principle with…

FinancialGenericsLegalMerck & CoPharmaceuticalProtonixTeva Pharmaceutical IndustriesVytorinZetia

Mylan settles Provigil litigation with Teva

10-06-2012

US generic major Mylan (Nasdaq: MYL) says that its subsidiary Mylan Pharmaceuticals has resolved all…

CephalonFinancialGenericsLegalMylan LaboratoriesNeurologicalNorth AmericaProvigilTeva Pharmaceutical Industries

Novartis posts sharp drop in 1st-qtr profit; challenges UK off-label Avastin use

24-04-2012

Swiss drug major Novartis (NOVN: VX) has reported a sharp fall in first-quarter 2012 profits, due in…

AvastinEuropeFinancialGenericsLegalLucentisNovartisOphthalmicsPharmaceutical

Sanofi fourth-quarter in line with forecasts; collects damages

08-02-2012

French drug major Sanofi (Euronext: SAN) this morning reported 8.8% growth in fourth-quarter 2011 sales…

ApotexBristol-Myers SquibbFinancialGenericsLegalPatentsPharmaceuticalPlavix

Ranbaxy signs consent decree with US FDA over production practices

22-12-2011

India’s largest drugmaker Ranbaxy Laboratories (RANB: BO), which is 64% owned by Japan’s Daiichi…

Daiichi SankyoFinancialGenericsLegalNorth AmericaPharmaceuticalRanbaxy LaboratoriesRegulation

Spain hopes to save 2.4 billion euros by ordering doctors to Rx generics

25-08-2011

As part of moves to reduce the nation’s budget deficit, Spain’s socialist government has passed…

EuropeFinancialGenericsLegalPharmaceuticalRegulation

Company Spotlight

ImmunoGen

ImmunoGen

Back to top